Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.
Other equities analysts have also issued reports about the company. Zacks Research raised Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. HC Wainwright decreased their target price on shares of Cartesian Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. BTIG Research restated a “buy” rating and set a $44.00 price target on shares of Cartesian Therapeutics in a report on Tuesday, June 9th. Weiss Ratings upgraded shares of Cartesian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Cartesian Therapeutics in a research note on Tuesday, June 9th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.
Get Our Latest Stock Analysis on RNAC
Cartesian Therapeutics Price Performance
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.46 EPS for the quarter, topping the consensus estimate of ($0.88) by $1.34. Research analysts expect that Cartesian Therapeutics will post -3.99 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cartesian Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. R Squared Ltd acquired a new stake in Cartesian Therapeutics during the fourth quarter worth approximately $74,000. Sei Investments Co. acquired a new position in Cartesian Therapeutics in the first quarter valued at approximately $78,000. Wells Fargo & Company MN lifted its stake in Cartesian Therapeutics by 49.2% in the fourth quarter. Wells Fargo & Company MN now owns 11,762 shares of the company’s stock valued at $85,000 after buying an additional 3,878 shares during the period. Miller Financial Services LLC boosted its holdings in shares of Cartesian Therapeutics by 17.2% during the 4th quarter. Miller Financial Services LLC now owns 13,643 shares of the company’s stock worth $98,000 after buying an additional 2,000 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Cartesian Therapeutics during the 4th quarter worth approximately $112,000. Institutional investors own 86.95% of the company’s stock.
Cartesian Therapeutics Company Profile
Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.
At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.
Read More
- Five stocks we like better than Cartesian Therapeutics
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
